← FDA DRUG APPROVALS

FDA ANDA · ANDA216414

LEVOTHYROXINE SODIUM

Sponsor: AUROBINDO PHARMA

APPLICATION
ANDA216414
TYPE
ANDA
ORIGINAL APPROVAL
2024-07-16
LATEST ACTION
2024-07-16
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

LEVOTHYROXINE SODIUMDiscontinued
LEVOTHYROXINE SODIUM 0.2MG · TABLET · ORAL
LEVOTHYROXINE SODIUMDiscontinued
LEVOTHYROXINE SODIUM 0.15MG · TABLET · ORAL
LEVOTHYROXINE SODIUMDiscontinued
LEVOTHYROXINE SODIUM 0.3MG · TABLET · ORAL
LEVOTHYROXINE SODIUMDiscontinued
LEVOTHYROXINE SODIUM 0.175MG · TABLET · ORAL
LEVOTHYROXINE SODIUMDiscontinued
LEVOTHYROXINE SODIUM 0.137MG · TABLET · ORAL

Approval history

2024-07-16UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →